By Stacey May
One of the most exciting parts of my job is working with my skilled colleagues to review all of the breakthrough scientific abstracts being presented at the AAPS annual meetings, workshops, and conferences. This year, we examined over 2,500 abstracts, four of which we will be highlighting on the AAPS Blog this week.
The first, which is being presented at 1:30 pm PST today, demonstrates how scientists have developed a novel topical microbicide loaded with hyaluronic acid (HA) nanofibers that could potentially prevent transmission of the human immunodeficiency virus (HIV) through the vaginal mucosa. The work was developed by Bi-Botti Youan, Ph. D and his colleagues from University of Missouri-Kansas City School of Pharmacy.
HIV is an infectious virus that attacks T lymphocytes, a type of white blood cell that prevents infections and disease. Over time, HIV dramatically depletes the body’s T cell population, leaving the body defenseless against opportunistic pathogens. HIV is transmitted through direct contact with blood, semen, pre-seminal fluid, vaginal fluids, rectal fluids, or breast milk from an infected person. According to AIDS.gov, the Center for Disease Control and Prevention estimates that more than 1 million persons aged 13 years and older are living with HIV infection, including 180,900 who are unaware that they have the virus. To date, there is no functional cure for HIV infection/AIDS. Currently available anti-HIV drug delivery methods are formulated as gels and suppositories, but can lack appropriate vaginal retention, are prone to medicine leakage, and may cause uncomfortable wetness.
To address these issues, Youan and his colleagues developed an anti-HIV drug loaded onto a mucoadhesive HA nanofiber delivery system. This delivery system is intended to stop HIV transmission through the vaginal mucosa, providing a triggered release upon exposure to semen fluid during sexual intercourse. The researchers used an electrospinning method to prepare the nanofibers loaded with tenofovir, a topical anti-HIV compound. Both semen enzyme-dependent nanofiber degradation and drug release were then measured using chemical and analytical assays. The cytotoxic effects of the nanofibers on human vaginal cells and on the Lactobacilli bacteria (L. crispatus) present in vaginal flora were also assessed.
The nanofiber-based formulation offers various potential advantages in vaginal drug delivery, including the ability to adapt delivery systems for different medical needs, with no leakage or messiness after their application. Furthermore, this technology could be beneficial in protecting drug molecules against enzymatic and other degradation that can occur in the body. Since human semen is the carrier of HIV virus transmission during male to female intercourse, a semen enzyme-triggered nanofiber delivery system as used in this study has the potential to inactivate or kill the HIV virus prior to exposure and penetration of the vaginal mucosa.
The next stage of Youan’s research is to examine the safety and efficacy of the HA-based nanofiber templates. Further in vivo studies will be carried out using animal models to characterize the viral transmission, inhibition, potential biodistribution, pharmacokinetics, vaginal retention time, safety, and immunological responses to the nanofibers.
This work was supported by grant number R01AI087304 from the National Institute of Allergy and Infectious Diseases (Bethesda, MD).
This blog post is adapted from the full press release.